Diabetes charity Diabetes UK has linked up with Bristol-Myers Squibb and AstraZeneca to launch a nationwide patient survey. The aim of the study is to find out more about hypoglycaemia . Together, the pharmaceutical companies will start to market a type 2 diabetes drug called Onglyza later on this year.
The patient survey is timed to fit in with Diabetes Week next week. Chief Executive of Diabetes UK, Douglas Smallwood, reportedly commented: “Although we already know a lot about severe hypoglycaemia, little has been done to investigate mild-to-moderate episodes, which people can experience on a regular basis.”
The medical director of Astrazeneca UK, Dr. Yeoma, was meanwhile reported in the media as saying: “We hope the results of the survey will raise the understanding and awareness of mild-to-moderate hypos and lead to the improved management of type II diabetes across the UK.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…